No Data
Express News | Traws Pharma Inc - No Significant Adverse Events Reported in Phase I Study
Express News | Traws Pharma Announces Completion of Phase I Studies With Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Traws Pharma Files to Sell 7.23M Shares of Common Stock for Holders
Traws Pharma Shares Surge 57% in After-Hours Trading Following Antiviral Trial Update
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Express News | Expert Systems: With Completion of Phase 1 Trials, Plans Are Underway to Initiate Phase 2 Efficacy Studies in First Half of 2025
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
kill everyone 
